Multiplex pan-filovirus assay performance and reproducibility across varied geographical and resource settings
Open Access
- 20 August 2026
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0356257
Abstract
Multiplex bead-based immunoassays (MIAs) are promising tools for simultaneously detecting humoral immunity to multiple targets, potentially playing a crucial role in serosurveillance and vaccine response assessments. However, evaluation of assay performance is paramount prior to widespread use. This study presents a performance evaluation of a pan-filovirus MIA through characterization of the analytical range for the EBOV glycoprotein (GP) target and assessments of assay precision and antigen discrimination. The precision of the MIA was evaluated by comparing the detection of anti-filovirus antibodies at two independent laboratory sites: the University of Hawai’i, Honolulu (UH), and the Institut National de Recherche Biomédicale (INRB) in Kinshasa, Democratic Republic of the Congo (DRC). Forty-six samples from Yambuku, DRC, including Ebola virus Disease (EVD) survivors and close contacts, were tested at both sites. Additionally, 907 samples were tested in DRC before and after vaccination with a prophylactic EVD vaccine, ERVEBO. Results demonstrated low variability between laboratories, with intra-assay and inter-laboratory coefficients of variation below predefined thresholds for all filovirus targets included in the multiplex panel. Analyte correlation between sites was high (r 2 = 0.86–0.92). Longitudinal analysis detected increased EBOV GP reactivity following vaccination, while reactivity to non-vaccine filovirus antigens remained stable, consistent with minimal cross-reactivity in a vaccinated cohort. These findings suggest that this pan-filovirus MIA produces reproducible results across distinct laboratory settings and may serve as a useful tool for comparative serologic investigations, serosurveillance, and evaluation of EBOV vaccine-associated antibody responses.Keywords
Funding Information
- U.S. Food and Drug Administration (75F40119C10128)
- Bill and Melinda Gates Foundation (OPP1195609)
This publication has 19 references indexed in Scilit:
- Thermostable bivalent & trivalent filovirus vaccines from insect cells: potency demonstrated after 3 months and 2 yearsVaccine, 2025
- Comparison of EBOV GP IgG antibody reactivity: Results from two immunoassays in the Democratic Republic of the CongoJournal of Virological Methods, 2025
- Case fatality rate for Ebola disease, 1976–2022: A meta-analysis of global dataJournal of Infection and Public Health, 2023
- Lyophilized Filovirus Glycoprotein Vaccines: Peroxides in a Vaccine Formulation with Polysorbate 80–Containing Adjuvant are Associated with Reduced Neutralizing Antibody Titers in Both Mice and Non-Human PrimatesJournal of Pharmaceutical Sciences, 2022
- Single-vial filovirus glycoprotein vaccines: Biophysical characteristics and immunogenicity after co-lyophilization with adjuvantVaccine, 2021
- Validation of a commercially available SARS-CoV-2 serological immunoassayClinical Microbiology and Infection, 2020
- A practical guide to validation and verification of analytical methods in the clinical laboratory2019
- Analytical performance of a commercial multiplex Luminex-based cytokine panel in the ratJournal of Pharmacological and Toxicological Methods, 2018
- Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in miceVaccine, 2017
- ISOLATION AND PARTIAL CHARACTERISATION OF A NEW VIRUS CAUSING ACUTE HÆMORRHAGIC FEVER IN ZAIREThe Lancet, 1977